Treatment of T-cell non-Hodgkin's lymphoma

Current Treatment Options in Oncology

Volumn 5, Issue 4, 2004, Pages 289-303

  Evens, Andrew M ^b   Gartenhaus, Ronald B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAPLASTIC LYMPHOMA KINASE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; NUCLEOPHOSMIN; NUCLEOSIDE ANALOG; PREDNISONE; PROCARBAZINE; PROTEIN P53; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RETINOBLASTOMA PROTEIN; RETINOIC ACID DERIVATIVE; TENIPOSIDE; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; AMENORRHEA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ASTHENIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTONOMIC DYSFUNCTION; AZOOSPERMIA; BACKACHE; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE; CEREBELLUM DISEASE; CHILL; CHROMOSOME REARRANGEMENT; CLINICAL TRIAL; CONFUSION; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DIAGNOSTIC TEST; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG COST; DRUG CROSS REACTIVITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DYSPHAGIA; DYSPNEA; EPSTEIN BARR VIRUS; FEASIBILITY STUDY; FEMALE INFERTILITY; FEVER; FLU LIKE SYNDROME; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HEADACHE; HEART INFARCTION; HELICOBACTER PYLORI; HEMORRHAGIC CYSTITIS; HUMAN; HYPERPIGMENTATION; HYPOTENSION; ILEUS; INFECTION; INSOMNIA; KIDNEY FAILURE; KIDNEY TUBULE NECROSIS; LARGE CELL LYMPHOMA; LEUKOPENIA; LIFESTYLE; LIVER CELL DAMAGE; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TOXICITY; LONG TERM CARE; LUNG FIBROSIS; LYMPHOCYTOPENIA; MALE INFERTILITY; MEDICAL DOCUMENTATION; MENTAL DISEASE; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAIL COLOR DEFECT; NAUSEA AND VOMITING; NERVOUSNESS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OBSTRUCTIVE JAUNDICE; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PHAGOCYTOSIS; PROTO ONCOGENE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; SURVIVAL RATE; SYNCOPE; T CELL LEUKEMIA; T CELL LYMPHOMA; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; URINE RETENTION; VASCULAR DISEASE; VIRUS CARCINOGENESIS;

EID: 4344658549     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0020-8     Document Type: Review

References (75)

1. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F: Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997, 89:4514-4520.
2. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998, 16:2780-2795.
3. Gisselbrecht C, Gaulard P, Lepage E, et al.: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood, 1998. 92:76-82.
4. Rudiger T, Weisenburger DD, Anderson JR, et al.: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002, 13:140-149.
5. Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835-3849.
6. Siegel RS, Pandolfino T, Guitart J, et al.: Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000, 18:2908-2925.
7. Pellatt J, Sweetenham J, Pickering RM, et al.: A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Ann Hematol 2002, 81:267-272.
8. Itoyama T, Chaganti RS, Yamada Y, et al.: Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. Blood 2001, 97:3612-3620.
9. Anagnostopoulos I, Hummel M, Stein H: Frequent presence of latent Epstein-Barr virus infection in peripheral T-cell lymphomas: a review. Leuk Lymphoma 1995, 19:1-12.
10. Luppi M, Barozzi P, Maiorana A, et al.: Human herpesvirus-8 DNA sequences in human immunodeficiency virus-negative angioimmunoblastic lymphadenopathy and benign lymphadenopathy with giant germinal center hyperplasia and increased vascularity. Blood 1996, 87:3903-3909.
11. d'Amore F, Johansen P, Houmand A, et al.: Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Danish Lymphoma Study Group, LYFO. Blood 1996, 87:1045-1055.
12. Hayday AC, Barber DF, Douglas N, Hoffman ES: Signals involved in gamma/delta T cell versus alpha/beta T cell lineage commitment. Semin Immunol 1999, 11:239-249.
13. Evens AM, Gartenhaus RB: Molecular etiology of mature T-cell non-Hodgkin's lymphomas. Front Biosci 2003, 8:D156-D175.
14. Reiser M, Josting A, Soltani M, et al.: T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 2002, 43:805-811.
15. Karakas T, Bergmann L, Stutte HJ, et al.: Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk Lymphoma 1996, 24:121-129.
16. Ansell SM, Habermann TM, Kurtin PJ, et al.: Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997, 15:2296-2301.
17. Jemal A, Murray T, Samuels A, et al.: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26.
18. Gordon LI, Harrington D, Andersen J, et al.: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992, 327:1342-1349.
19. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
20. Kurzrock R: Therapy of T-cell lymphomas with pentostatin. Ann N Y Acad Sci 2001, 941:200-205.
21. Iannitto E, Barbera V, Quintini G, et al.: Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin. Br J Haematol 2002, 117:995-996.
22. Sallah S, Wan JY, Nguyen NP: Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001, 113:185-187.
23. Zinzani PL, Magagnoli M, Bendandi M, et al.: Therapy with gemcitabine in pretreated. peripheral T-cell lymphoma patients. Ann Oncol 1998, 9:1351-1353.
24. LeMaistre CF, Saleh MN, Kuzel TM, et al.: Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998, 91:399-405.
25. Talpur R, Apisarnthanarax N, Ward S, Duvic M: Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma 2002, 43:121-126.
26. Huang CL, Lin ZZ, Su IJ, et al.: Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma. Leuk Lymphoma 2002, 43:1415-1420.
27. Siegert W, Nerl C, Agthe A, et al.: Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 1995, 6:659-664.
28. Sallah S, Gagnon GA: Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment. Acta Haematol 1998, 99:57-64.
29. Siegert W, Agthe A, Griesser H, et al.: Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen: a multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992, 117:364-370.
30. Quintini G, Iannitto E, Barbera V, et al.: Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma. Hematol J 2001, 2:393-395.
31. Tsatalas C, Margaritis D, Kaloutsi V, et al.: Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine. Acta Haematol 2001, 105:106-108.
32. Stein H, Foss HD, Durkop H, et al.: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000, 96:3681-3695.
33. Tilly H, Gaulard P, Lepage E, et al.: Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood 1997, 90:3727-3734.
34. Kutok JL, Aster JC: Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 2002, 20:3691-3702.
35. Gascoyne RD, Aoun P, Wu D, et al.: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999, 93:3913-3921.
36. Suzuki P, Kagami Y, Takeuchi K, et al.: Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 2000, 96:2993-3000.
37. Falini B, Pileri S, Zinzani PL, et al.: ALK+ lymphoma: clinico-pathological findings and outcome. Blood 1999, 93:2697-2706.
38. Seidemann K, Tiemann M, Schrappe M, et al.: Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001, 97:3699-3706.
39. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al.: Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000, 95:3653-3661.
40. Kumar S, Krenacs L, Medeiros J, et al.: Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes. Hum Pathol 1998, 29:397-403.
41. Salhany KE, Macon WR, Choi JK, et al.: Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol 1998, 22:881-893.
42. Marzano AV, Berti E, Paulli M, Caputo R: Cytophagic histiocytic panniculitis and subcutaneous panniculitis-like T-cell lymphoma: report of 7 cases. Arch Dermatol 2000, 136:889-896.
43. u WY, Ng WM, Choy C, Kwong YL: Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone. Br J Dermatol 2000, 143:408-410.
44. Cooke CB, Krenacs L, Stetler-Stevenson M, et al.: Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996, 88:4265-4274.
45. Weidmann E: Hepatosplenic T cell lymphoma: a review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000, 14:991-997.
46. Hanson MN, Morrison VA, Peterson BA, et al.: Post-transplant T-cell lymphoproliferative disorders: an aggressive, late complication of solid-organ transplantation. Blood 1996, 88:3626-3633.
47. Cheung MM, Chan JK, Lau WH, et al.: Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998, 16:70-77.
48. Kim GE, Cho JH, Yang WI, et al.: Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000, 18:54-63.
49. Li YX, Coucke PA, Li JY, et al.: Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998, 83:449-456.
50. Kim GE, Lee SW, Chang SK, et al.: Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001, 61:261-269.
51. Gale J, Simmonds PD, Mead GM, et al.: Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000, 18:795-803.
52. Quintanilla-Martinez L, Lome-Maldonado C, Ott G, et al.: Primary non-Hodgkin's lymphoma of the intestine: high prevalence of Epstein-Barr virus in Mexican lymphomas as compared with European cases. Blood 1997, 89:644-651.
53. Hoffmann M, Vogelsang H, Kletter K, et al.: 18F-fluorodeoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut 2003, 52:347-351.
54. El-Sabban ME, Nasr R, Dbaibo G, et al.: Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000, 96:2849-2855.
55. Bazarbachi A, El-Sabban ME, Nast R, et al.: Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999, 93:278-283.
56. Dierov J, Sawaya BE, Prosniak M, Gartenhaus RB: Retinoic acid modulates a bimodal effect on cell cycle progression in human adult T-cell leukemia cells. Clin Cancer Res 1999, 5:2540-2547.
57. Matutes E, Taylor GP, Cavenagh J, et al.: Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001, 113:779-784.
58. Hermine O, Allard I, Levy V, et al.: A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002, 3:276-282.
59. Besson C, Panelatti G, Delaunay C, et al.: Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk Lymphoma 2002, 43:2275-2279.
60. Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
61. Kahl C, Leithauser M, Wolff D, et al.: Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. Ann Hematol 2002, 81:646-650.
62. Blystad AK, Enblad G, Kvaloy S, et al.: High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001, 27:711-716.
63. Rodriguez J, Munsell M, Yazji S, et al.: impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001, 19:3766-3770.
64. Song KW, Mollee P, Keating A, Crump M: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003, 120:978-985.
65. Deconinck, E, Lamy T, Foussard C, et al.: Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. Br J Haematol 2000, 109:736-742.
66. Fanin R, Sperotto A , Silvestri F, et al.: The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. Leuk Lymphoma 1999, 35:159-169.
67. Okamura T, Kishimoto T, Inoue M, et al.: Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant 2003, 31:105-111.
68. Nagata S, Onda M, Numata Y, et al.: Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res 2002, 8:2345-2355.
69. Hatta Y, Koeffler HP: Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia 2002, 16:1069-1085.
70. Hofmann WK, Tsukasaki K, Takeuchi N, et al.: Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001, 42:1107-1109.
71. Piekarz RL, Robey R, Sandor V, et al.: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001, 98:2865-2868.
72. Bariol C, Field A, Vickers CR, Ward R: Regression of gastric T cell lymphoma with eradication of Helicobacter pylori. Gut 2001, 48:269-271.
73. Fillmore GC, Lin Z, Bohling SD, et al.: Gene expression profiling of cell lines derived from T-cell malignancies. FEBS Lett 2002, 522:183-188.
74. Passoni L, Scardino A, Bertazzoli C, et al.: ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002, 99:2100-2106.
75. Thirdborough SM, Radcliffe JN, Friedmann PS, Stevenson FK: Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. Cancer Res 2002, 62:1757-1760.